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PHeart Rhythm Disorders
Catheter Ablation for Atrial Fibrillation
Are Results Maintained at 5 Years of Follow-Up?
Rukshen Weerasooriya, BMEDSC(HONS), MBBS,*† Paul Khairy, MD, PHD,‡ Jean Litalien, MD,*
Laurent Macle, MD,‡ Meleze Hocini, MD,* Frederic Sacher, MD,* Nicolas Lellouche, MD,*
Sebastien Knecht, MD,* Matthew Wright, PHD, MD,* Isabelle Nault, MD,* Shinsuke Miyazaki, MD,*
Christophe Scavee, MD,* Jacques Clementy, MD,* Michel Haissaguerre, MD,* Pierre Jais, MD*
Bordeaux-Pessac, France; Crawley, Western Australia; and Montreal, Quebec, Canada
Objectives This study describes 5-year follow-up results of catheter ablation for atrial fibrillation (AF).
Background Long-term efficacy following catheter ablation of AF remains unknown.
Methods A total of 100 patients (86 men, 14 women), age 55.7  9.6 years, referred to our center for a first AF ablation
(63% paroxysmal; 3.5  1.4 prior ineffective antiarrhythmic agents) were followed for 5 years. Complete suc-
cess was defined as absence of any AF or atrial tachycardia recurrence (clinical or by 24-h Holter monitoring)
lasting 30 s.
Results Arrhythmia-free survival rates after a single catheter ablation procedure were 40%, 37%, and 29% at 1, 2,
and 5 years, respectively, with most recurrences over the first 6 months. Patients with long-standing persis-
tent AF experienced a higher recurrence rate than those with paroxysmal or persistent forms (hazard ratio
[HR]: 1.9, 95% confidence interval [CI]: 1.0 to 3.5; p  0.0462). In all, 175 procedures were performed,
with a median of 2 per patient. Arrhythmia-free survival following the last catheter ablation procedure was
87%, 81%, and 63% at 1, 2, and 5 years, respectively. Valvular heart disease (HR: 6.0, 95% CI: 2.0 to 17.6;
p  0.0012) and nonischemic dilated cardiomyopathy (HR: 34.0, 95% CI: 6.3 to 182.1; p  0.0001) inde-
pendently predicted recurrences. Major complications (cardiac tamponade requiring drainage) occurred in
3 patients (3%).
Conclusions In selected patients with AF, a catheter ablation strategy with repeat intervention as necessary provides accept-
able long-term relief. Although most recurrences transpire over the first 6 to 12 months, a slow but steady de-
cline in arrhythmia-free survival is noted thereafter. (J Am Coll Cardiol 2011;57:160–6) © 2011 by the
American College of Cardiology Foundation














Patheter ablation that predominantly targets pulmonary
eins (PVs) is well established as a treatment option for
atients with symptomatic drug refractory atrial fibrillation
AF), with a steady growth in the number of interventions
erformed over the past decade (1). Although recent con-
ensus guidelines emphasize the important need for long-
erm result reporting (1), most studies have limited
ollow-up to 1 year or less, with few outcome data beyond 3
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ccepted May 28, 2010.ears. Because the substrate for AF may evolve in a
ime-dependent fashion, the critically important question
rises as to whether ablation simply slows disease pro-
ression or confers relatively stable long-term arrhythmia
ontrol. Longer-term outcomes are particularly impor-
ant when one considers that catheter ablation is gener-
lly offered to relatively young patients compared with
he overall population afflicted with AF. Longer-term
utcomes are also highly relevant in modeling and
omparing the cost-effectiveness of treatment strategies.
e, therefore, sought to assess 5-year outcomes in a
ohort of patients with AF ablation at a single center
sing a uniform approach.
ethods
atient characteristics. A group of 100 patients who under-
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January 11, 2011:160–6 Atrial Fibrillation Ablation: 5-Year Follow-Up002 were prospectively followed to determine long-term
utcomes. All procedures were performed at Hopital Car-
iologique du Haut-Leveque, Bordeaux-Pessac, using a stan-
ard ablation protocol. Inclusion criteria consisted of the follow-
ng:
. Age between 18 and 80 years.
. Symptomatic and/or complicated AF (i.e., stroke, tran-
sient ischemic attack, or heart failure).
. History of documented AF exceeding 6 months. AF was
classified as paroxysmal (episodes 7 days) or persistent
(7-day episodes) or long standing persistent (1).
. Episodes of AF lasting longer than 1 h per week despite
a trial of at least 2 antiarrhythmic agents or monotherapy
with amiodarone.
. Provision of patient-informed consent.
Patients with any of the following criteria were excluded
rom this analysis:
. Reversible cause for AF (such as hyperthyroidism),
. Prior AF ablation attempts (surgical- or catheter-based),
. Residing outside of France,
. History of AF 6 months,
. 1 h per week of AF (on average).
re-ablation preparation. Antiarrhythmic drugs were dis-
ontinued 5 half-lives prior to ablation, except for amioda-
one, which was discontinued the preceding week. All
atients received oral anticoagulation with warfarin for a
inimum of 1 month before ablation, targeting interna-
ional normalized ratio levels between 2 and 3. Warfarin was
iscontinued 5 days before ablation and substituted by
ubcutaneous enoxaparin (1.5 mg/kg twice daily). Trans-
sophageal echocardiography was performed within 4 days
f ablation to exclude left atrial thrombi.
atheter ablation procedure. PROCEDURAL CHARACTERISTICS.
ll procedures were performed with local anesthesia under
onscious sedation, administered by the anesthesia service.
oninvasive blood pressure monitoring and continuous digital
ulse oximetry were performed throughout the procedure.
Three vascular sheaths (i.e., 6-, 7-, and 8-F) were
nserted in the right femoral vein under lidocaine local
nesthesia. A steerable quadripolar catheter (2-5-2 mm,
trem, ELA Medical, Montrouge, France) was positioned
n the coronary sinus. The 8-F sheath was upgraded to a
ong sheath (Preface 62 cm, Biosense-Webster, Diamond-
ar, California). Transseptal puncture was performed using
standard needle (Adult BRK 71 cm, St. Jude Medical, St.
aul, Minnesota) by means of a 2-in-1 technique. An
blation catheter (Thermocool D curve 5-mm tip, Biosense-
ebster) was subsequently advanced to the left atrium.
ontrast hand injection of all PVs was performed in the
uoroscopic anteroposterior projection using a multipurpose
atheter (N.I.H., Cordis Corp., Bridgewater, New Jersey).
n order to map PV potentials, a fixed diameter (20 mm)
teerable decapolar circumferential catheter (Lasso, Biosense- webster) was advanced via the
ong sheath.
Surface electrocardiograms
nd bipolar intracardiac electro-
rams were continuously moni-
ored using the LabSystem Pro
Bard Electrophysiology, Lowell, Massachusetts). Signals
ere sampled at 1 kHz, filtered at 0.1 to 100 Hz for surface
lectrocardiograms and at 30 to 250 Hz for intracardiac
ignals, and displayed at an amplification of 0.1 mV/cm.
ATHETER ABLATION. All segmental ostial PVs were sys-
ematically isolated and the cavotricuspid isthmus was
blated in every patient. Left atrial linear ablation of the roof
nd mitral isthmus was generally reserved for patients with
ersistent or long-standing persistent AF, those in whom
F continued despite PV isolation, and recurrent cases.
blation techniques have been previously described (2–4).
riefly, radiofrequency energy was delivered at the PV
stium using a Cordis-Stockert generator at a temperature
etting of 50°C, with a power limit of 30 W for the right
uperior PV, left superior PV, and right inferior PV, and
5 W for the left inferior PV due to the higher reported
ncidence of stenosis. Normal saline (0.9%) was infused
hrough the ablation catheter at a pump rate of 2 ml/min
uring mapping and 10 to 60 ml/min during radiofrequency
elivery. Ablation end points consisted of complete elimi-
ation or dissociation of PV potentials and bidirectional
inear block.
OST-OPERATIVE CARE. Patients were hospitalized for 3
ays following catheter ablation, with continuous rhythm
onitoring. The day after the intervention, all patients had
ransthoracic echocardiography to exclude a pericardial ef-
usion or other detectable complications. Oral anticoagula-
ion was reinstituted the day after ablation and subcutaneous
eparin injections were continued until international nor-
alized ratio levels exceeded 2. All patients were treated
ith warfarin for at least 1 to 3 months after ablation.
ollowing this, anticoagulation requirements were individ-
alized. Anticoagulants were generally discontinued in pa-
ients deemed recurrence-free and with no other indications
or anticoagulation such as prosthetic valves, ischemic
troke, or transient ischemic attack, or other thromboem-
olic events. In case of recurrent AF, warfarin was reintro-
uced in preparation for a repeat procedure and/or if
linically indicated. In the absence of arrhythmia recurrence
uring this initial surveillance period, antiarrhythmic drugs
ere not represcribed. In the event of early AF recurrence,
atients with and without structural heart disease received
miodarone (100 to 200 mg daily) or flecainide (100 to 300
g daily), respectively. Bisoprolol (2.5 to 5 mg) was
rescribed to patients with sinus tachycardia following
blation. Antiarrhythmic agents were discontinued after 1
onth if the patient was able to maintain sinus rhythm.
ollow-up. Over the first year, follow-up appointments
Abbreviations
and Acronyms
AF  atrial fibrillation
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Atrial Fibrillation Ablation: 5-Year Follow-Up January 11, 2011:160–6uring each such visit, patients were hospitalized for the
ollowing investigations: 24-h Holter monitoring, transtho-
acic echocardiography, and exercise stress testing. Between
isits, all patients were encouraged to seek 12-lead electro-
ardiographic documentation for any symptoms suggestive
f AF. If AF recurrence was observed, the patient was
ffered reablation. Atrial tachycardia and atrial flutter were
lassified as ablation failure. After a minimum of 5 years
ollowing the first catheter ablation procedure, patients were
eadmitted to hospital to undergo 24-h Holter monitoring,
ransthoracic echocardiography, and exercise stress testing,
nd a standard questionnaire was administered (Online
ppendix). Success was defined as the absence of symptoms
r episodes of AF/atrial tachycardia or flutter greater than
0 s duration off antiarrhythmic agents.
tatistical analysis. Categorical variables are represented
y frequencies and percentages. Continuous variables are
ummarized by mean  SD or median and interquartile
ange (IQR) (25th, 75th percentile) depending on normality
f distribution. Time to recurrence and event-free survival
urves were estimated by the Kaplan-Meier product-limit
ethod. Univariate and multivariate predictors of recurrent
F following the first and final catheter ablation procedures
ere assessed in Cox regression models, after verifying
roportionality assumptions. Candidate variables with p val-
es 0.20 in univariate analyses were considered in multi-
ariate stepwise regression models. Two-tailed p values
0.05 were considered statistically significant. Analyses
ere performed with SAS software (version 9.1, SAS
nstitute, Cary, North Carolina).
esults
aseline and procedural characteristics. During the study
eriod, 552 patients underwent ablation for AF at our
enter. Patients followed outside of France were excluded
n  64), as were those with prior ablation (n  256), 1 h
f AF per week on average (n 98), and a history of AF6
onths (n  34). The study cohort consists of the remain-
ng 100 patients, 86% men, age 55.7  9.6 years.
Baseline characteristics are summarized in Table 1. Seven
atients had idiopathic dilated cardiomyopathy defined as
ilation and systolic ventricular dysfunction in the absence of
ongenital, valvular, coronary artery, or any systemic disease
nown to cause myocardial dysfunction. Valvular heart disease
as defined as stenosis or regurgitation of any heart valve
reater than “mild” by echocardiographic criteria.
In all, 175 procedures were performed, with a median of
(IQR: 1, 2) per patient as follows: 49 had 1, 34 had 2, 13
ad 3, and 4 had 4 to 7 interventions. Figure 1 provides an
verview of recurrences and repeat interventions. The pre-
ominant indication for a repeat procedure was AF in 45
60%) and other atrial tachyarrhythmias in 30 (40%) pa-
ients. Even though all patients had PV isolation and
avotricuspid isthmus ablation, left atrial linear ablation was
erformed in 92 patients and consisted of left isthmus pblation in 89 (70 during the first procedure) and/or roofline
blation in 13 (5 during the first procedure). At the time of
he first procedure, 32 patients were on amiodarone; at
epeat procedures, 6 patients were on amiodarone.
ollow-up. Patients were followed for a median of 60
IQR: 56, 62) months from the first procedure and 54
IQR: 51, 60) months from the last procedure. Three deaths
ccurred over the course of follow-up, none deemed cardiac
n origin (lung cancer, n  1; cerebral hematoma in an
nticoagulated patient at 17 months after ablation, n  1;
nd suicide, n  1).
rrhythmia-free survival after a single procedure. Actu-
rial arrhythmia-free survival rates after a single catheter
blation procedure were 39.8  5.1%, 36.5  5.0%, and
8.5  4.7% at 1, 2, and 5 years, respectively. As shown in
igure 2, most recurrences occurred during the first 6
onths, with an actuarial event-free survival rate of 44.2 
.1%. After a single procedure, the only univariate predictor
f recurrence was type of AF, with long-standing persistent
F associated with a hazard ratio (HR) of 1.9, 95%
onfidence interval (CI): 1.0 to 3.5, p  0.0462, when
ompared with paroxysmal or persistent forms.
Arrhythmias recurred in 10 of 36 (28%) patients who had
aintained sinus rhythm for at least 1 year. Of the 68
aseline Characteristics (n  100)Table 1 Baseline Characteristics (n  100)
Demographic variables
Age at inclusion, yrs 55.7 9.6
Male sex, % 86
Medical history




History of atrial fibrillation, months 72 54
Structural heart disease, % 36
Ischemic 8
Left ventricular hypertrophy 16
Valvular heart disease 5
Idiopathic dilated cardiomyopathy 7
Left ventricular ejection fraction, % 70 11
Risk factors for thromboembolism, %
Hypertension 43
Diabetes 3
Congestive cardiac failure 9







Number of ineffective antiarrhythmic drugs 3.5 1.4
Failed amiodarone therapy, % 67
Major amiodarone-related complication, % 10
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January 11, 2011:160–6 Atrial Fibrillation Ablation: 5-Year Follow-Upnterventions for the following reasons: spontaneous or
ntiarrhythmic-mediated resolution of symptoms (n  7),
atient refusal (n  3), infrequent and/or mild residual
ymptoms (n 6), and morbid obesity (n 1). In all except
cases of purely asymptomatic AF recurrence, recurrence
as symptomatic at least some of the time. Fifty-one
atients underwent repeat procedures targeting PV conduc-
ion recovery in all and gaps in linear lesions in 28 patients.
rrhythmia-free survival since last intervention. Actu-
rial arrhythmia-free survival rates following the last cath-
ter ablation procedure were 87.1 3.5%, 81.4 4.1%, and
2.9  5.4% at 1, 2, and 5 years, respectively. Of the 77
atients who were arrhythmia-free at 1 year of follow-up, 19
25%) presented with a later recurrence. In the 7 patients
ith repeat interventions (5 for AF; 2 for left atrial flutter),
he following nonexclusive observations were noted: PV
econnection (n 6), linear lesion gap (n 4), non-PV foci
n  3), and left atrial flutter without previous linear
blation (n  1). Multiple substrates for recurrence were
dentified in all but 2 patients (non-PV foci in 1 patient; PV
Figure 1 Study Flow Chart
Flow-chart delineating recurrences and repeat interventions.econnection in 1 patient). aFigure 3 displays the slow but steady decline in
rrhythmia-free survival corresponding to an average actu-
rial event rate of 8.9% per year. Univariate predictors of
ecurrence were long-standing persistent AF (HR: 2.6, 95%
I: 1.1 to 6.0; p  0.0319), presence of valvular heart
isease (HR: 5.2, 95% CI: 1.8 to 15.2; p  0.0026), and
onischemic dilated cardiomyopathy (HR: 26.8, 95% CI:
.1 to 140.1; p  0.0001). Valvular heart disease (HR: 6.0,
5% CI: 2.0 to 17.6; p  0.0012) and nonischemic dilated
ardiomyopathy (HR: 34.0, 95% CI: 6.3 to 182.1; p 
.0001) remained independent predictors of recurrent AF in
ultivariate analyses. The 64 patients with paroxysmal AF
t baseline did not progress to persistent or permanent AF
uring the course of the study follow-up.
omplications. There were no procedure-related deaths.
omplications were as follows: cardiac tamponade (surgical
ntervention, n  3), pericardial effusion managed conser-
atively (n  3), asymptomatic 70% PV stenosis (n  1),
rteriovenous femoral fistulae (n  1), femoral false aneu-
ysm (n  1), anaphylactic shock secondary to propofol
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Atrial Fibrillation Ablation: 5-Year Follow-Up January 11, 2011:160–6ry to intraprocedural direct current cardioversion (n  1).
o late or unexpected complications were detected at 5-year
ollow-up.
iscussion
erein, we report the longest follow-up to date of any
ercutaneous AF procedure. By 5 years of follow-up,
reedom from recurrent AF was 63%, albeit with repeat
nterventions in 51%. Moreover, we observed a gradual
ttrition in arrhythmia-free survival, with an 8.9% annual
ecurrence rate following the last ablation attempt. Notably,
he long-term effectiveness of a single procedure was mod-
st, with 29% arrhythmia-free survival at 5 years. No new or
nforeseen sequelae of catheter ablation were detected
eyond periprocedural complications, with no thromboem-
olic events or clinically significant PV stenosis. These
esults have implications for the long-term follow-up of
atients after radiofrequency catheter ablation for AF.
The long-term success rates in our study are consistent
ith prior reports of 70% at 20 months (5) and 66% at 26
onths (6) and an 8.7% long-term recurrence rate at 28
onths described by Shah et al. (7). In further extending
he follow-up period, we noted that the rate of decline in
reedom from AF after the first intervention stabilized after
he initial 12 months, although it did not entirely plateau.
linical implications of these results are substantial with
egard to the care of patients with AF. Firstly, empirical
ong-term follow-up data should be presented to patients to
nform the decision-making process and provide reasonable
xpectations. Secondly, ongoing surveillance is warranted,
ven if catheter ablation was deemed initially successful. In
ccordance with the recently published consensus statement
1), patients with a previous history of stroke should not
iscontinue anticoagulation therapy.
Late recurrences and frequent reinterventions should also
Figure 2 Single Procedure Success
Kaplan-Meier event-free survival curve after a single catheter ablation attempt.e factored into cost-modeling assessments, as these proce-ures become more widely performed and increasingly
nfluence overall health care expenditure. Although prior
tudies have concluded that the net benefit of catheter
blation over medical therapy extends to approximately
years (8,9), projected costs have not considered later (i.e.,
3 years) recurrences and reinterventions. For example,
haykin et al. (9) assumed a maximum 5% late recurrence
ate, which underestimates results from our long-term
ndings. Given that patients in this study were relatively
oung, with an average age of 55 years at entry, extending
ollow-up even further would be of interest in determining
he likelihood of AF recurrence over a lifespan.
Patients had a median of 2.0 procedures, reflecting a
reatment strategy favoring early reintervention for recur-
ences (10). The high rate of repeat procedures accounts, in
art, for the marked disparity between event-free survival
ates following single and final interventions. The benefit of
epeat interventions is partly captured by the difference
etween these actuarial event rates. Need for repeat inter-
entions and recurrent arrhythmias were modulated by type
f AF at baseline, with long-standing persistent AF being a
nivariate predictor of recurrence. Despite the clinical ob-
ervation that persistent AF cases are more difficult to treat
nd require a higher number of procedures (11,12), type of
F was not a predictor of outcome in the multivariate
nalysis.
Importantly, our study population was not representative
f patients with AF at large, as it consisted predominantly of
ounger, healthier, nonobese patients with relatively smaller
tria and paroxysmal or recent progression to persistent AF.
Electrophysiological mechanisms underlying early recur-
ences following PV isolation have been extensively studied.
n recurrences 3 months after ablation, Gerstenfeld et al.
13) found that 61% of PVs had recovered conduction.
allans et al. (14) reported that PV reconnection accounted
or 77% of recurrences. Extending the follow-up to 12
onths, Mainigi et al. (15) found that 75% of implicated
Figure 3 Multiple Procedure Success
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January 11, 2011:160–6 Atrial Fibrillation Ablation: 5-Year Follow-Upoci were within PVs, although 30% had not been previously
argeted. Notably, Hsieh et al. (16) reported that PV foci
ere less likely to be responsible for recurrences beyond 12
onths. Using a segmental PV isolation technique, Solheim
t al. (6) noted recurrences 12 months (mean 26  11
onths) in 8 of 187 (4%) patients with paroxysmal AF,
hereas Cheema et al. (17) reported a success rate of 69% at
6  11 months in a subgroup with paroxysmal AF
onsidered “ideal” candidates for PV isolation. In our series,
nly 7 of 31 patients with recurrences after 12 months were
estudied and most (i.e., 6 patients) had PV reconnection.
inimizing the likelihood of PV reconnection appears,
herefore, to be a worthy objective. Some investigators have
uggested that propensity for PV reconnection may be
ssessed acutely by administering an adenosine bolus (18) or
etesting 30 and 60 min after ablation (19). Techniques to
chieve optimal safety and efficiency remain in evolution,
ncluding different energy modalities, delivery platforms,
nd novel biological solutions.
Late recurrences of AF may reflect dynamic alterations in
he underlying substrate as well as the impact of associated
iseases such as hypertension, sleep apnea, and diabetes on
atural history of AF. Antifibrotic and antifibrillatory effects
f nonantiarrhythmic drugs such as angiotensin-converting
nzyme and angiotensin 2 inhibitors are increasingly appre-
iated and may potentially improve long-term outcomes by
reventing such remodeling (20,21). The side-effect profile
f these agents is also attractive in comparison to antiar-
hythmic drugs. Nevertheless, although these agents may
old promise, supporting evidence from clinical research is
equired before routinely adopting these treatment strate-
ies. Although our study did not particularly target preven-
ive measures, previous studies suggest that long-term ben-
fit may be derived from careful efforts to control
ypertension and sleep apnea, and avoidance of weight gain
22–24).
tudy limitations. These results may not be generalized as
hey were observed in a single, relatively high volume “early
eveloper” experience. Monitoring for AF recurrence in this
arlier cohort of patients was not as extensive as recom-
ended by the recently published consensus statement. The
otential for under-recognition of silent AF therefore exists.
owever, because AF ablation in this patient cohort was
erformed for symptomatic control, symptomatic AF recur-
ence remains a clinically valid end point. Study conclusions
ust be interpreted in light of this caveat. Under-
ecognition of silent AF should, however, heighten concerns
or eliminating long-term anticoagulation among those at
isk.
Similarly, computed tomography scanning or magnetic
esonance imaging was not routinely performed at the end
f the 5-year follow-up to detect asymptomatic PV stenosis,
lthough patients were specifically questioned with regard to
V stenosis symptoms and imaging was performed to rule
ut a suspected diagnosis.Furthermore, the approach to AF ablation has changed
rom an ostial or segmental approach to a more circumfer-
ntial approach and the procedure used nowadays consisting
f a larger encircling of the ipsilateral veins has been shown
o be more effective. As a consequence, we suspect that the
uccess rate reported here is at least equal if not better using
urrent techniques.
onclusions
n selected patients with AF, a catheter ablation strategy
ith repeat intervention as necessary provides acceptable
ong-term relief from symptomatic recurrences. Although
ost recurrences transpire over the first 6 to 12 months, a
low but steady decline in arrhythmia-free survival is noted
hereafter, even after 3 or more years of apparent arrhythmia
ontrol. Such long-term follow-up data should be openly
iscussed with patients, factored into management deci-
ions, and incorporated into cost-effectiveness models that
ssess the merits of an ablation approach.
eprint requests and correspondence: Dr. Rukshen Weera-
ooriya, Hôpital Cardiologique du Haut-Lévêque, 33604
ordeaux-Pessac, France. E-mail: rukshen@afablationclinic.
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APPENDIX
or a copy of the questionnaire used during follow-up,
lease see the online version of this article.
